$EVFM
Evofem Biosciences, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459017010425 Filed on May 11, 2017

View on sec.gov

Income Statement

Concept 2016 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.520M
YoY Change 29.9%
% of Gross Profit
Research & Development $3.260M
YoY Change -30.65%
% of Gross Profit
Depreciation & Amortization $20.00K
YoY Change
% of Gross Profit
Operating Expenses $5.781M
YoY Change -12.91%
Operating Profit -$5.781M
YoY Change -12.91%
Interest Expense -$250.0K
YoY Change -3.85%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.030M
YoY Change -12.61%
Income Tax
% Of Pretax Income
Net Earnings -$6.027M
YoY Change -12.69%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.633M
COMMON SHARES
Basic Shares Outstanding 13.75M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.10M
YoY Change -65.91%
Cash & Equivalents $24.10M
Short-Term Investments
Other Short-Term Assets $1.100M
YoY Change 37.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.20M
YoY Change -64.75%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K
YoY Change -17.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K
YoY Change 0.0%
Total Long-Term Assets $300.0K
YoY Change -31.97%
TOTAL ASSETS
Total Short-Term Assets $25.20M
Total Long-Term Assets $300.0K
Total Assets $25.50M
YoY Change -64.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M
YoY Change -26.22%
Accrued Expenses $1.700M
YoY Change 6.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $800.0K
YoY Change 64.02%
Total Short-Term Liabilities $3.900M
YoY Change -1.92%
LONG-TERM LIABILITIES
Long-Term Debt $3.200M
YoY Change -65.59%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $3.200M
YoY Change -65.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.900M
Total Long-Term Liabilities $3.200M
Total Liabilities $7.000M
YoY Change -47.27%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.50M
YoY Change
Total Liabilities & Shareholders Equity $25.50M
YoY Change -64.54%

Cashflow Statement

Concept 2016 Q1
OPERATING ACTIVITIES
Net Income -$6.027M
YoY Change -12.69%
Depreciation, Depletion And Amortization $20.00K
YoY Change
Cash From Operating Activities -$7.610M
YoY Change 58.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $485.9K
YoY Change
Cash From Financing Activities -6.050M
YoY Change
NET CHANGE
Cash From Operating Activities -7.610M
Cash From Investing Activities 0.000
Cash From Financing Activities -6.050M
Net Change In Cash -13.66M
YoY Change 161.19%
FREE CASH FLOW
Cash From Operating Activities -$7.610M
Capital Expenditures $0.00
Free Cash Flow -$7.610M
YoY Change 51.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
12535
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5781169
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1476259
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2520871
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3026171
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
5781169
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3026171
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
19737
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
265124
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3013636
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6026556
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13807622
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13757582
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
11663
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17776
CY2017Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-55705
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
39793
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
131096
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
714687
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-175954
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-901697
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
795545
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3253731
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1843673
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7606334
CY2017Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
5500
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
5500
CY2016Q1 us-gaap Early Repayment Of Senior Debt
EarlyRepaymentOfSeniorDebt
5514058
CY2016Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
485942
CY2016Q1 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
52400
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
144729
CY2017Q1 neot Non Cancelable Operating Lease Agreement Date
NonCancelableOperatingLeaseAgreementDate
2015-01-20
CY2017Q1 neot Lease Expiration Period
LeaseExpirationPeriod
2020-03
CY2017Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
71257
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
871203
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
370000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3459
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3459
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-6052400
CY2017Q1 neot Net Increase Decrease In Cash Cash Equivalents And Restricted Cash
NetIncreaseDecreaseInCashCashEquivalentsAndRestrictedCash
-1834714
CY2016Q1 neot Net Increase Decrease In Cash Cash Equivalents And Restricted Cash
NetIncreaseDecreaseInCashCashEquivalentsAndRestrictedCash
-13658734
CY2016Q4 neot Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
11677852
CY2015Q4 neot Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
37948603
CY2017Q1 neot Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
9843138
CY2016Q1 neot Cash Cash Equivalents And Restricted Cash At Carrying Value
CashCashEquivalentsAndRestrictedCashAtCarryingValue
24289869
CY2016Q1 us-gaap Interest Paid
InterestPaid
230924
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3251
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&nbsp;&nbsp;Actual results could differ from those estimates.</p></div>
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
391716
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1546
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1236406
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
200000
CY2017Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1307663
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1191835
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
100577
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
254049
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
64125
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.95
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.43
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.06
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.96
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.50
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
131096
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714687
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2460765
CY2017Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4342888
CY2017Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.</p></div>
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
410848
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
431507
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
109293
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1343364
CY2017Q1 neot Operating Leases Future Minimum Payments Due Remainder Of Fiscal Year Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueRemainderOfFiscalYearFutureMinimumSubleaseRentals
124956
CY2017Q1 neot Operating Leases Future Minimum Payments Due In Two Years Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueInTwoYearsFutureMinimumSubleaseRentals
342374
CY2017Q1 neot Operating Leases Future Minimum Payments Due In Three Years Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueInThreeYearsFutureMinimumSubleaseRentals
352645
CY2017Q1 neot Operating Leases Future Minimum Payments Due In Four Years Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueInFourYearsFutureMinimumSubleaseRentals
90143
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
910118

Files In Submission

Name View Source Status
0001564590-17-010425-index-headers.html Edgar Link pending
0001564590-17-010425-index.html Edgar Link pending
0001564590-17-010425.txt Edgar Link pending
0001564590-17-010425-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
neot-10q_20170331.htm Edgar Link pending
neot-20170331.xml Edgar Link completed
neot-20170331.xsd Edgar Link pending
neot-20170331_cal.xml Edgar Link unprocessable
neot-20170331_def.xml Edgar Link unprocessable
neot-20170331_lab.xml Edgar Link unprocessable
neot-20170331_pre.xml Edgar Link unprocessable
neot-ex311_8.htm Edgar Link pending
neot-ex321_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending